Skip to main content
Erschienen in: Infection 2/2011

01.04.2011 | Clinical and Epidemiological Study

Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption

verfasst von: S. Bagaglio, G. Bianchi, A. Danise, L. Porrino, C. Uberti-Foppa, A. Lazzarin, A. Castagna, G. Morsica

Erschienen in: Infection | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

The prevalence and clinical significance of overt hepatitis B (OHB) in human immunodeficiency virus (HIV)-infected individuals and the effect of HAART on this cryptic infection remain controversial. We have investigated the potential effect of the interruption and subsequent re-introduction of highly active antiretroviral therapy (HAART) on the frequency and dynamics of OHB in HIV-infected individuals.

Study design

This pilot study involved 29 HIV-infected individuals who tested positive for HB anti-core antibodies in the absence of surface antigen during a 100-week period (48-week-long interruption of HAART or lamivudine monotherapy plus 52 weeks of follow-up prior to HAART resumption). The frequency and dynamics of OHB were assessed by means of qualitative detection tests and quantification in the plasma. Resistance to HBV was determined by direct sequence analysis of the polymerase gene.

Results

Of the 29 HIV-infected individuals enrolled in the study, nine (31%) showed signs of OHB during the 100-week study period: three patients showed intermittent HB virus (HBV)-DNAemia, while six patients were HBV-DNA positive only at 16 weeks following HAART resumption. The HBV-DNA load invariably fell below the sensitivity of the quantitative test (10copies/mL). The HIV-related immuno-virologic profile and biochemical parameters, including hepatic transaminases, of patients with at least one HBV-DNA positive test result were not significant different from those of individuals who consistently tested negative for HBV-DNA. The only significant parameter was a lower median change (Δ1) in the CD4+/CD8+ ratio (p = 0.038) in occult HBV cases compared to non-occult cases, between the HAART re-introduction time point and baseline.

Conclusions

The intermittent nature of HBV-DNAemia poses a diagnostic challenge, but no association was found with transaminase levels at any time.
Literatur
1.
Zurück zum Zitat Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–70.PubMedCrossRef Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–70.PubMedCrossRef
2.
Zurück zum Zitat Fang Y, Shang QL, Liu JY, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009;58:383–8.PubMedCrossRef Fang Y, Shang QL, Liu JY, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009;58:383–8.PubMedCrossRef
3.
Zurück zum Zitat Jardim RN, Gonçales NS, Pereira JS, Fais VC, Gonçales Junior FL. Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis. 2008;12:300–5.PubMedCrossRef Jardim RN, Gonçales NS, Pereira JS, Fais VC, Gonçales Junior FL. Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis. 2008;12:300–5.PubMedCrossRef
4.
Zurück zum Zitat Piroth L, Lafon ME, Binquet C, et al. Occult hepatitis B in HIV-HCV coinfected patients. Scand J Infect Dis. 2008;31:1–5.CrossRef Piroth L, Lafon ME, Binquet C, et al. Occult hepatitis B in HIV-HCV coinfected patients. Scand J Infect Dis. 2008;31:1–5.CrossRef
5.
Zurück zum Zitat Fabris P, Biasin MR, Giordani MT, et al. Impact of occult HBV infection in HIV/HCV co-infected patients: HBV-DNA detection in liver specimens and in serum samples. Curr HIV Res. 2008;6:173–9.PubMedCrossRef Fabris P, Biasin MR, Giordani MT, et al. Impact of occult HBV infection in HIV/HCV co-infected patients: HBV-DNA detection in liver specimens and in serum samples. Curr HIV Res. 2008;6:173–9.PubMedCrossRef
6.
Zurück zum Zitat Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects. J Infect Dis. 2003;188:571–7.PubMedCrossRef Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects. J Infect Dis. 2003;188:571–7.PubMedCrossRef
7.
Zurück zum Zitat Chamorro AJ, Casado JL, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only marker. Eur J Clin Microbiol Infect Dis. 2005;24:492–4.PubMedCrossRef Chamorro AJ, Casado JL, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only marker. Eur J Clin Microbiol Infect Dis. 2005;24:492–4.PubMedCrossRef
8.
Zurück zum Zitat Bloquel B, Jeulin H, Burty C, Letranchant L, Rabaud C, Venard V. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort. J Med Virol. 2010;82:206–12.PubMedCrossRef Bloquel B, Jeulin H, Burty C, Letranchant L, Rabaud C, Venard V. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort. J Med Virol. 2010;82:206–12.PubMedCrossRef
9.
Zurück zum Zitat Schnepf N, Sellier P, Bendenoun M, Sanson-le Pors MJ, Mazeron MC. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol. 2007;39:48–50.PubMedCrossRef Schnepf N, Sellier P, Bendenoun M, Sanson-le Pors MJ, Mazeron MC. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol. 2007;39:48–50.PubMedCrossRef
10.
Zurück zum Zitat Clark SJ, Creighton S, Horner M, et al. Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression. Int J STD AIDS. 2006;17:67–9.PubMedCrossRef Clark SJ, Creighton S, Horner M, et al. Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression. Int J STD AIDS. 2006;17:67–9.PubMedCrossRef
11.
Zurück zum Zitat Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20:795–803.PubMedCrossRef Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20:795–803.PubMedCrossRef
12.
Zurück zum Zitat Morsica G, Ancarani F, Bagaglio S, et al. Occult hepatitis B virus infection in a cohort of HIV positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection. 2009;37:445–9.PubMedCrossRef Morsica G, Ancarani F, Bagaglio S, et al. Occult hepatitis B virus infection in a cohort of HIV positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection. 2009;37:445–9.PubMedCrossRef
13.
Zurück zum Zitat Morsica G, Bagaglio S, Cicconi P, et al. Viral interference between Hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr. 2009;51:574–81.PubMedCrossRef Morsica G, Bagaglio S, Cicconi P, et al. Viral interference between Hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr. 2009;51:574–81.PubMedCrossRef
14.
Zurück zum Zitat Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36:681–6.PubMedCrossRef Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36:681–6.PubMedCrossRef
15.
Zurück zum Zitat Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253–60.PubMedCrossRef Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253–60.PubMedCrossRef
16.
Zurück zum Zitat Laguno M, Larrousse M, Blanco JL, et al. Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients. AIDS Res Hum Retroviruses. 2008;24:547–53.PubMedCrossRef Laguno M, Larrousse M, Blanco JL, et al. Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients. AIDS Res Hum Retroviruses. 2008;24:547–53.PubMedCrossRef
17.
Zurück zum Zitat Allain JP, Belkhiri D, Vermeulen M, et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology. 2009;49:1868–76.PubMedCrossRef Allain JP, Belkhiri D, Vermeulen M, et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology. 2009;49:1868–76.PubMedCrossRef
18.
Zurück zum Zitat Nebbia G, Garcia-Diaz A, Ayliffe U, et al. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol. 2007;79:1464–71.PubMedCrossRef Nebbia G, Garcia-Diaz A, Ayliffe U, et al. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol. 2007;79:1464–71.PubMedCrossRef
19.
Zurück zum Zitat Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol. 2009;8:441–5.CrossRef Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol. 2009;8:441–5.CrossRef
Metadaten
Titel
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption
verfasst von
S. Bagaglio
G. Bianchi
A. Danise
L. Porrino
C. Uberti-Foppa
A. Lazzarin
A. Castagna
G. Morsica
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Infection / Ausgabe 2/2011
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-011-0093-9

Weitere Artikel der Ausgabe 2/2011

Infection 2/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.